| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
3'-Deoxyguanosine targets purine nucleoside phosphorylase and other enzymes involved in nucleoside metabolism. As a purine nucleoside analog, it has broad antitumor activity and targets indolent lymphoid system malignancies. The anticancer mechanism depends on inhibition of DNA synthesis and induction of apoptosis. The compound can be complexed with enzymes and receptors to study structure-activity relationships. The lack of the 3'-hydroxyl group prevents chain elongation during DNA synthesis, leading to chain termination.
|
|---|---|
| ln Vitro |
3'-Deoxyguanosine is a ligand that can be complexed with enzymes such as purine nucleoside phosphorylase and receptors. It has broad antitumor activity targeting indolent lymphoid system malignancies. The anticancer mechanism depends on inhibition of DNA synthesis and induction of apoptosis. As a nucleoside analog, it is incorporated into DNA during replication, leading to chain termination and inhibition of cell proliferation. The compound can also be used to selectively impair transcription.
|
| ln Vivo |
In vivo studies for 3'-Deoxyguanosine have not been extensively documented in the available literature. As a purine nucleoside analog with broad antitumor activity, it has potential for in vivo efficacy in cancer models. The compound's mechanism involves inhibition of DNA synthesis and induction of apoptosis. Studies in appropriate animal models would be needed to evaluate its in vivo efficacy, pharmacokinetics, and safety profile. The compound is a vital nucleoside analog used in the synthesis of antiviral agents and cancer therapeutics.
|
| Enzyme Assay |
For enzyme binding assays, purine nucleoside phosphorylase or other target enzymes are incubated with 3'-Deoxyguanosine at various concentrations. Binding affinity is measured by surface plasmon resonance, isothermal titration calorimetry, or fluorescence quenching. For enzyme inhibition studies, the enzyme is incubated with the substrate and inhibitor, and activity is measured by spectrophotometric or radiometric methods. For DNA synthesis inhibition assays, DNA polymerase is incubated with template, primers, nucleotides, and the compound, and incorporation is measured by gel electrophoresis or scintillation counting.
|
| Cell Assay |
For anticancer activity evaluation, cancer cell lines are cultured in appropriate media. Cells are seeded in 96-well plates and treated with 3'-Deoxyguanosine at various concentrations for 48-72 hours. Cell viability is assessed using MTT or SRB assays, and IC50 values are calculated. DNA synthesis inhibition is assessed by measuring incorporation of radiolabeled thymidine or by BrdU incorporation assays. Apoptosis induction is evaluated by Annexin V-FITC/PI staining and flow cytometry, or by caspase-3/7 activity assays. Cell cycle analysis is performed using propidium iodide staining.
|
| Animal Protocol |
For in vivo efficacy studies, immunocompromised mice bearing tumor xenografts would be administered 3'-Deoxyguanosine intraperitoneally or orally at various doses. Tumor volume would be measured twice weekly using calipers, and body weight monitored for toxicity. At study termination, tumors would be collected for histopathological analysis and assessment of apoptosis. However, detailed in vivo protocols for 3'-Deoxyguanosine have not been extensively reported in the literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 3'-Deoxyguanosine have not been fully characterized in the available literature. The compound has a molecular weight of 267.24 and is a nucleoside analog with moderate water solubility. As a nucleoside analog, it is expected to be taken up by cells and phosphorylated to the active form. The lack of the 3'-hydroxyl group may affect its metabolism and incorporation into nucleic acids. Comprehensive PK studies including bioavailability, half-life, protein binding, and tissue distribution are needed.
|
| Toxicity/Toxicokinetics |
3'-Deoxyguanosine is a research compound intended for laboratory use only and is not approved for human therapeutic use. As a purine nucleoside analog, it has broad antitumor activity and targets indolent lymphoid system malignancies. The anticancer mechanism depends on inhibition of DNA synthesis and induction of apoptosis. Standard laboratory safety precautions should be followed when handling this compound. The compound can be used to selectively impair transcription.
|
| References | |
| Additional Infomation |
3'-Deoxyguanosine is a 3'-deoxynucleoside with guanine as its nucleobase. It is an EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor. It is a 3'-deoxynucleoside belonging to the guanosine class of compounds. 3'-Deoxyguanosine is a solid. This compound belongs to the purine nucleoside and its analogues. These compounds are composed of purine bases linked to sugars. This drug targets purine nucleoside phosphorylase.
3'-Deoxyguanosine is a purine nucleoside analog with molecular formula C10H13N5O4 and molecular weight 267.24. It is a ligand for enzymes such as purine nucleoside phosphorylase and receptors. The compound has broad antitumor activity targeting indolent lymphoid system malignancies through inhibition of DNA synthesis and induction of apoptosis. It is used in the synthesis of antiviral agents and cancer therapeutics. The compound is for research use only and has not been approved for clinical applications. It can also be used to selectively impair transcription. |
| Molecular Formula |
C10H13N5O4
|
|---|---|
| Molecular Weight |
267.24
|
| Exact Mass |
267.096
|
| CAS # |
3608-58-0
|
| PubChem CID |
135440068
|
| Appearance |
Off-white to brown solid powder
|
| Density |
2.1±0.1 g/cm3
|
| Boiling Point |
725.5±70.0 °C at 760 mmHg
|
| Melting Point |
<300℃ (water )
|
| Flash Point |
392.6±35.7 °C
|
| Vapour Pressure |
0.0±2.5 mmHg at 25°C
|
| Index of Refraction |
1.907
|
| LogP |
-0.72
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
417
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C1[C@H](O[C@H]([C@@H]1O)N2C=NC3=C2N=C(NC3=O)N)CO
|
| InChi Key |
OROIAVZITJBGSM-OBXARNEKSA-N
|
| InChi Code |
InChI=1S/C10H13N5O4/c11-10-13-7-6(8(18)14-10)12-3-15(7)9-5(17)1-4(2-16)19-9/h3-5,9,16-17H,1-2H2,(H3,11,13,14,18)/t4-,5+,9+/m0/s1
|
| Chemical Name |
2-amino-9-[(2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (374.20 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.35 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.35 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7420 mL | 18.7098 mL | 37.4195 mL | |
| 5 mM | 0.7484 mL | 3.7420 mL | 7.4839 mL | |
| 10 mM | 0.3742 mL | 1.8710 mL | 3.7420 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA